Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Will New Antibiotic Incentives GAIN Investors’ Backing?

13 Aug 2012

• By Jessica Merrill

Related Content

Labeling For Optimer's Dificid Includes Data On Ability To Sustain Cure Post-Treatment

27 May 2011

With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation

13 Aug 2012

Moving Beyond <em>Cubicin</em>: Cubist Sets The Stage For Long-Term Growth

07 May 2012

Optimer’s Dificid Could Pave A Path To Higher Prices For Antibiotics

23 Jan 2012

FDA Continues To Clarify Antibiotic Requirements With New Guidance On Complicated UTI

05 Mar 2012

Rib-X Teams With Sanofi To Develop Novel, Broad-Spectrum Antibiotics

06 Jul 2011

Related Companies

AstraZeneca PLC

Bayer AG

GSK plc

Trius Therapeutics, Inc.

Pfizer Inc.

Cubist Pharmaceuticals, Inc.

ViroPharma Inc.

Melinta Therapeutics, Inc.

PolyMedix, Inc.

Melinta Therapeutics, Inc.

The Medicines Company

Merck & Co., Inc.

Additional Topics

Clinical Trials Regulation Reimbursement BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.